Troutman Pepper Advises Palvella Therapeutics in Merger With Pieris Pharmaceuticals
July 25, 2024
July 25, 2024
ATLANTA, Georgia, July 25 -- Troutman Pepper, a law firm, issued the following news:
PHILADELPHIA - Troutman Pepper client Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) have entered into a definitive merger agreement to combine the companies in an all-stock transaction. Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, Inc., will be headquartered i . . .
PHILADELPHIA - Troutman Pepper client Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) have entered into a definitive merger agreement to combine the companies in an all-stock transaction. Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, Inc., will be headquartered i . . .